Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events – – First Patient Dosed in Phase 2 Trial of SLS009 ...
MetaOptics Ltd (Catalist: 9MT) ('MetaOptics' or the 'Company', and together with its subsidiaries, the 'Group') recently announced a series of strategic growth initiatives on SGXNet, including a ...
Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the future of gene editing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results